Search results
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 2 days agoThough it has a booster Covid shot, like rivals Moderna and Novavax, analysts don't expect sales to...
We Won't Solve Long COVID Until We Decide What It Is
Medscape· 4 days agoIs a slow recovery from COVID-19 the lingering effects of a bad infection or the start of a new syndrome?
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoThe company noted that it achieved 48% market share for Covid vaccines in the U.S. during the fall...
Texas Biomed expanding animal research complex with $20 million building
San Antonio Express-News· 2 days agoThe Texas Biomedical Research Institute is continuing expansion of a new animal research complex on...
FDA recommends COVID jab manufacturers update formulas to combat new strain
BizPac Review· 7 days agoA new strain of COVID has prompted recommendations for vaccine companies to update their formulas in anticipation of cases in the fall. The U.S. Food and Drug Administration (FDA) announced ...
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day...
Benzinga· 4 days agoShares of Quantum Corporation QMCO fell sharply during Tuesday's session after the company reported...
COVID vaccine companies told to focus on KP.2 variant for fall shots, per FDA announcement
AOL· 7 days agoThe U.S. Food and Drug Administration (FDA) has recommended that COVID vaccine manufacturers update their formulas for fall doses, in an attempt to target the KP.2 strain of the JN.1 variant ...